Concepedia

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia V. Zhukova,

The Lancet Oncology · 2022 · 104 citations · 14 references

DOI

Concepts

References

14

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

Stephen B. Edge, Carolyn C. Compton · Annals of Surgical Oncology · 2010 · 9.2K citations · Full text

, , +14

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +16

Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma

Georgina V. Long, Alexander M. Menzies, Adnan Nagrial et al. · Journal of Clinical Oncology · 2011 · 1K citations · Full text

, , +17

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 1K citations

, , +11

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2020 · 650 citations

, , +15